Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 2/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.32 |
| ▸ | MME | P08473 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277564 | 0.95 | CYP2C19 (0.52) | CYP2C19CETPTBXAS1FFAR3CYP4F2 | |
| SCHEMBL887735 | 0.93 | CYP2C19 (0.56) | CYP2C19CETPTBXAS1FFAR3CYP4F2 | |
| Hydrochloric Acid SCHEMBL9565686 | 0.91 | CYP2C19 (0.54) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 | |
| SCHEMBL3153596 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL11613521 | 0.88 | CYP2C19 (0.38) | CYP2C19CETPTBXAS1FFAR3MME | |
| SCHEMBL1327047 | 0.86 | CYP2C19 (0.43) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 | |
| SCHEMBL1911583 | 0.85 | CETP (0.42) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 | |
| Cyanide SCHEMBL11468844 | 0.84 | CYP2C19 (0.35) | CYP2C19CETPFFAR3 | |
| SCHEMBL5610724 | 0.83 | TBXAS1 (0.44) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 | |
| SCHEMBL3953039 | 0.82 | CYP2C19 (0.48) | CYP2C19CETPTBXAS1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3147284-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2017-03-29 | — | — | EP | disclosed |
| US-7423067-B2 | N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse | MERCK & CO., INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423067-B2 | N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse | MERCK & CO., INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423067-B2 | N-(3,4-diphenyl-2-butyl)cyclopentancarboxamide derivatives such as N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-3-benzoyl-cyclopentane-carboxamide; used for treating conditions including psychological disorders, eating disorders and substance abuse | MERCK & CO., INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080076805-A1 | Acyclic Hydrazides as Cannabinoid Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1807388-A2 | ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1490043-A4 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| WO-2003082190-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| US-4833157-A | ANTIULCER AGENTS | MILES INC. (US) | 1989-05-23 | — | — | US | disclosed |
| US-4742080-A | Therapeutic method for producing bronchodilation by administration of 15-deoxy-16-hydroxy prostaglandin esters | MILES LABORATORIES, INC. (US) | 1988-05-03 | — | — | US | disclosed |
| US-4415592-A | ANTISECRETORY AND HYPOTENSIVE AGENTS | MILES LABORATORIES, INC. (US) | 1983-11-15 | — | — | US | disclosed |
| US-4331688-A | Therapeutic method for inhibiting gastric secretion by administration of 15-deoxy-16-hydroxy prostaglandins | MILES LABORATORIES, INC. (US) | 1982-05-25 | — | — | US | disclosed |
| US-4275224-A | BRONCHODIALATORS AND ANTI-GASTRIC SECRETION AGENTS | MILES LABORATORIES, INC. (US) | 1981-06-23 | — | — | US | disclosed |
| US-4132738-A | BRONCHODILATORS, ANTISECRETORY AGENTS | MILES LABORATORIES, INC. (US) | 1979-01-02 | — | — | US | disclosed |
| US-4117119-A | 15-CYCLOBUTYL-PROSTAGLANDINS | ONO PHARMACEUTICAL COMPANY (JP) | 1978-09-26 | — | — | US | disclosed |
| US-4045468-A | GASTRIC ULCERS | ONO PHARMACEUTICAL COMPANY (JA) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076805-A1 | Acyclic Hydrazides as Cannabinoid Receptor Modulators | CNR1, CNR2, FAAH | CYP2C19 1036/4885CETP 3170/4885TBXAS1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.